HC Wainwright Has Positive Estimate for ALDX FY2030 Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Investment analysts at HC Wainwright raised their FY2030 earnings per share estimates for Aldeyra Therapeutics in a report released on Monday, August 17th. HC Wainwright analyst M. Caufield now expects that the biotechnology company will post earnings of $0.36 per share for the year, up from their previous forecast of $0.34. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.43) per share.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09).

Other analysts have also issued research reports about the company. Weiss Ratings lowered Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 20th. Wall Street Zen lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Aldeyra Therapeutics currently has a consensus rating of “Hold” and an average price target of $5.50.

Aldeyra Therapeutics Stock Performance

Shares of ALDX stock opened at $1.56 on Tuesday. Aldeyra Therapeutics has a 1 year low of $1.07 and a 1 year high of $6.17. The business’s fifty day moving average is $1.80 and its 200-day moving average is $2.56. The stock has a market cap of $94.11 million, a PE ratio of -4.00 and a beta of 1.22.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of large investors have recently made changes to their positions in ALDX. 683 Capital Management LLC grew its position in Aldeyra Therapeutics by 86.6% during the 4th quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock worth $7,925,000 after purchasing an additional 710,000 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Aldeyra Therapeutics by 146.6% in the first quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company’s stock valued at $1,459,000 after purchasing an additional 513,187 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Aldeyra Therapeutics in the second quarter valued at $1,007,000. Bank of New York Mellon Corp boosted its position in shares of Aldeyra Therapeutics by 18.1% in the first quarter. Bank of New York Mellon Corp now owns 136,746 shares of the biotechnology company’s stock worth $231,000 after buying an additional 20,980 shares during the period. Finally, Hikari Power Ltd acquired a new stake in shares of Aldeyra Therapeutics in the second quarter worth $43,000. Institutional investors and hedge funds own 59.71% of the company’s stock.

Insider Buying and Selling

In other news, CEO Todd C. Brady bought 250,000 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was bought at an average cost of $1.67 per share, for a total transaction of $417,500.00. Following the completion of the acquisition, the chief executive officer directly owned 1,721,298 shares in the company, valued at $2,874,567.66. This represents a 16.99% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 11.80% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.